Press Releases for INCY

Press Releases
PicksThatMove.com Announces Investment Opinion on Bristol-Myers Squibb Co., Incyte Corp., EnCana Corporation, B2Gold Corp. and Medclean Technologies Inc.
Incyte Completes Offering of Convertible Senior Notes
Incyte Announces Closing of Public Offering of Common Stock
Incyte Prices $350 Million Convertible Senior Notes Offering
Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock
Incyte Announces Proposed Offering of $250 Million Convertible Senior Notes
Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock
Incyte Reports Second Quarter 2009 Financial Results and Provides Update on Drug Development Programs
Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis
Incyte to Report Second Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on July 30
StreetInvesting.Com Free Research on KLIC, ARCC, INCY, FORM, ACLS and DRIV
Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte’s Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterol in Patients with Type 2 Diabetes
Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis
Incyte to Present at Goldman Sachs 30th Annual Global Healthcare Conference
Incyte Reports First Quarter 2009 Financial Results and Provides Update on Drug Development Programs
Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7
Incyte to Present at Citi's 4th Annual Biotech Day Conference
Incyte to Present at Cowen and Company 29th Annual Health Care Conference
Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; Announces 2009 Financial Guidance
Incyte to Report 2008 Financial Results and 2009 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
Incyte to Announce 2009 Objectives at JPMorgan Healthcare Conference; JAK Inhibitor Program Highest Priority
Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference
Zacks Analyst Blog Highlights: Toyota Motor Corp., Whole Foods Market, Inc., Penn Virginia Resource Partners, Trident Microsystems Inc. And Lloyds TSB Group Plc.
Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results
Incyte to Present at 2008 DB-Biotech Boston Confab
Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients
Incyte to Report Third Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on November 6
Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time
Incyte to Present at JMP Securities Third Annual Healthcare Focus Conference
Incyte Appoints Chief Commercial Officer
Incyte's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients with Mild to Moderate Psoriasis
Incyte to Present at the UBS Global Life Sciences Conference
Incyte to Present at Upcoming Investor Conferences - Aug 27 2008 4:18PM
Incyte Announces Closing of Public Offering of Common Stock
Incyte Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
Incyte Announces Proposed Public Offering of 9,000,000 Shares of Common Stock
Incyte Reports Progress in Multiple Clinical Programs; Announces Second Quarter Financial Results
Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31
Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study
Incyte to Host EULAR Webcast and Conference Call on June 12
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics
Incyte to Present at Upcoming Investor Conferences - Jun 3 2008 4:51PM
Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study
Incyte Reports First Quarter Financial Results and Positive Clinical Progress in Multiple Programs
Incyte to Report First Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on April 30
Incyte to Present at Upcoming Investor Conferences - Jun 1 2008 11:15PM